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Abstract
Primary cicatricial alopecias (PCA) are a rare group of disorders in which the hair
follicle is the main target of destructive inflammation resulting in irreversible hair loss
with scarring of affected lesions. Inflammation may predominantly involve lympho-
cytes or neutrophils. Cicatricial alopecias that mainly involve lymphocytic inflammation
include lichen planopilaris, discoid lupus erythematosus, pseudopelade (Brocq), central
centrifugal alopecia, alopecia mucinosa, and keratosis follicularis spinulosa decalvans.
Cicatricial alopecias that are due to predominantly neutrophilic inflammation include
folliculitis decalvans and dissecting cellulitis of the scalp. Acne keloidalis, acne
necrotica, and erosive pustular dermatosis are cicatricial alopecias with a mixed inflam-
matory infiltrate.
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1. Introduction
Cicatricial alopecias are the result of various diseases of the scalp. It is usually circumscribed
but may be widespread [1]. It presents as areas of hair loss in which the underlying scalp is
scarred, sclerosed, or atrophic [1, 2]. In early stages, the underlying disease is usually diagnos-
able clinically and histologically, but in later stages, only scarring may be evident [3–5]. The
scarring is the result of the destruction and fibrosis of hair follicles [1, 6, 7]. The primary
cicatricial alopecias, which are the focus of this chapter, can be particularly challenging clini-
cally. Several classification schemes for primary cicatricial alopecia exist in the literature.
Workshop sponsored by the North American Hair Research Society, a working classification
of primary cicatricial alopecias based on the predominant inflammatory cellular infiltrate was
developed (Table 1) [8].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Lymphocytic cicatricial alopecias
2.1. Lichen planopilaris
Lichen planopilaris is a rare disease characterized by autoreactive lymphocytic destruction
of the hair follicle and is the cause of progressive cicatricial alopecia. Perifollicular erythema,
squams, and keratotic follicular papules are commonly encountered clinical findings of LPP
(Figure 1) [4, 9]. Although diagnosis can be made clinically and histopathologically in the
early stages, it becomes more difficult to diagnose in the late stages due to the absence of
specific findings [1, 5]. Lichen planopilaris can be subdivided into three groups including
classic lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome [4, 6].
Classic lichen planopilaris presents as scalp hair involvement and is sometimes accompanied
by extracranial lichen forms. Frontal fibrosing alopecia is characterized by band-like scarring
alopecia of the frontal hairline that usually affects middle-aged women. Graham-Little syn-
drome, also known as Graham-Little-Piccardi-Lasseur syndrome, is a disease having a triad
of cicatricial alopecia, lichen planus spinulosus, and nonscarring hair loss of axillary and
pubic area [1].
1—Lymphocytic
Lichen planopilaris
Classic lichen planopilaris
Frontal fibrosing alopecia
Graham-Little syndrome
Chronic cutaneous lupus erythematosus
Classic pseudopelade
Central centrifugal cicatricial alopecia
Alopecia mucinosa
Keratosis follicularis spinulosa decalvans
2—Neutrophilic
Folliculitis decalvans
Dissecting cellulitis
3—Mixed
Acne keloidalis
Acne necrotica
Erosive pustular dermatosis
4—Nonspecific
Table 1. Classification of primary cicatricial alopecias.
Hair and Scalp Disorders178
2.1.1. Classic lichen planopilaris
It was initially described by Pringle. It is more common in women than in men. Light-skinned
individuals are more frequently affected than dark-skinned individuals. Most patients visit a
doctor in the first year [1, 4, 10]. Although the etiology of lichen planopilaris is poorly under-
stood, the most widely accepted theory states that it is an autoimmune disorder in which
Langerhans cells-activated T lymphocytes destroy keratinocytes. In LPP, most T lymphocytes
are located around the bulge area. It is seen that cells in the bulge area are multipotent and are
important in generating anagen hair follicle. Destruction of follicular stem cells localized in the
bulge area is found to be significant in lichen planopilaris [4, 11]. Contact sensitizers such as
metals can enhance a T cell inflammatory reaction. Commonly encountered metals are gold,
mercury, and cobalt. The role of infection is determined in the development of LPP. These
infections include hepatitis C, HIV, HSV type 2, Helicobacter pylori, and HPV. It was observed
that antimalarial agents, beta-blockers, thiazides, ACE inhibitors aggravate lichen planopilaris,
and classic lichen planus [1, 3, 4, 12]. Although the pathogenesis of lichen planopilaris shows
extensive similarities to the lichen planus, some reports point out differences in
immunoreactant deposition. Lichenoid dermatitis is histopathologically detected at the
dermoepidermal junction around follicular infundibulum and isthmus. Occasionally similar
lichenoid changes may be observed at the papillary dermis between surface epithelium and
hair follicles. Mild to severe dyskeratosis and lymphocytic infiltration are encountered. How-
ever, epidermal and dermal mucin accumulation seen in DLE are not found [3, 4]. Immuno-
fluorescence evaluation may demonstrate the deposition of fibrinogen, IgM or rarely C3, and
IgA at the follicular basement membrane zone of the follicle in a linear pattern. Histopatholog-
ical findings vary according to disease progression and sometimes it may be difficult to
diagnose. It is especially difficult to diagnose in the late stages due to follicular scar. The biopsy
site selection is an important process to establish an exact diagnosis. It is recommended to
perform biopsy in areas particularly having active lesions. Active inflammatory areas are
Figure 1. Lichen planopilaris.
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squamous, erythematous, and also symptomatic [3, 13, 14]. First signs of LPP include alopecia
and pruritus. Rarely pain, burning, and seborrheic dermatitis are observed. The most frequent
clinical forms are perifollicular erythema and affinitative, violescent brown, hyperkeratotic
follicular papules and flat, atrophic, polygonal-sided alopecic plaques are subsequently
appeared following the aggregation of papules. Scalp lesions may be single or multiple, focal,
or wide. They are most frequently involved in the vertex and parietal area. Tiny alopecic
patches slowly proceed and bind with other patches causing reticular pattern. Pull test is
positive in the active periods [1, 4, 15]. Distinctive diagnosis of classic lichen planopilaris is
carried out with DLE, pseudopelade of Brocq, folliculitis decalvans, keratosis pilaris
spondiloza, alopecia mucinosa, and seborrheic dermatitis. The lack of pustules supports the
distinction from folliculitis decalvans. In the clinical manifestation, histopathologic and immu-
nohistochemical properties of LPP facilitate the differentiation from other diseases.
LPP is difficult to treat. Local and systemic therapies are used. Local therapies are initially
selected in most cases since they are relatively safe. The aim of therapy is to reduce subjective
symptoms and to prevent inflammation and progression [4, 15]. Topical and intralesional
corticosteroids are often chosen as the first-line therapy. However, best regimen of treatment
for topical corticosteroids in LPP is not known. High potent corticosteroids are mainly
selected. If there is no response to corticosteroid therapy, other alternative drugs should be
considered. Intralesional corticosteroid injections reduce inflammation significantly. However,
atrophy can occur. In progressive patients, prednisone, an oral corticosteroid, can be given at 1
mg/kg/day over 2–4 months. Relapse may occur following the withdrawal of systemic cortico-
steroid therapy. Hydroxychloroquine has an immunomodulatory property and is well toler-
ated. Effects of treatment are initiated within 2–3 months and maximal clinical efficacy may
take up to 6–12 months. 400 mg/day of oral hydroxychloroquine therapy is recommended
after liver function test, complete blood count, and ophthalmologic examination. Adverse
reactions are rare, but include abdominal pain, anorexia, nausea, myalgia, skin hyperpig-
mentation, and ophthalmologic damage. Smoking may decrease efficacy. Cyclosporine is
effective in lichen planus. There are reports with mycophenolate mofetil especially in patients
unresponsive to corticosteroids and hydroxychloroquine therapy demonstrating its efficacy
and lower side effect profile [3, 16]. Other treatment options include retinoids, tetracycline,
griseofulvin, thalidomide, dapsone, topical tacrolimus, and minoxidil. However, there effec-
tiveness is still controversial [4, 9].
2.1.2. Frontal fibrosing alopecia
Frontal fibrosing alopecia (FFA), first described by Kossard in 1994, is a form of lichen
planopilaris characterized by cicatricial alopecia at the frontoparietal hairline and it occurs
primarily in postmenopausal women. Although the disease occurred typically in postmeno-
pausal women, it is rarely seen in men too. A total of 80 cases have been reported so far [17,
18]. Etiopathogenesis of FFA is not fully understood. As most of the cases are postmenopausal,
hormone-related triggering mechanisms are thought to play role in the etiopathogenesis. In
some cases, successful usage of 5-alpha reductase inhibitors supports the latter. Some reports
state that the occurrence of familial cases of FFA points to a possible genetic contribution. The
most characteristic clinical feature of frontal fibrosing alopecia is the progressive recession of
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the frontal and parietal hairline. All FFA patients exhibit this finding which is required to
diagnose [17, 19, 20]. Hairline recession usually occurs symmetrically and bilaterally, giving
rise to a band of alopecia between 0.5 and 8 cm from its original site. The progression is
relatively slow, and erythema and hyperkeratosis papules indistinguishable from that seen in
LPP are common findings. Eyebrow loss or thinning was reported in 62.82% of patients.
Despite 50% of lichen planus lesions are observed in lichen planopilaris, the prevalence is only
5% in FFA [3, 17, 21]. Histopathological and immunofluorescence evaluations are similar to
classic lichen planopilaris. However, it is harder to diagnose in the late stages. Causes of
cicatricial alopecia should be considered in the differential diagnosis of FFA. Clinical features
of FFA differ from other alopecias by its histopathological features [1, 4, 22]. Precise, effective
treatment options are limited. There are no randomized clinical studies. Corticosteroids are
proper approach in the early stages. Systemic corticosteroids can be administered in the dose
of 0.5–3 mg/kg per day for a period of 3–18 months. Some studies demonstrated that topical
corticosteroids were not effective. Intralesional corticosteroid treatment used in the advanced
stages may even worsen the disease rather than improvement. Topical minoxidil revealed
controversial results. Mono- or combination therapy of finasteride produced successful results.
Other treatment options including griseofulvin, isotretinoin, tacrolimus, pimecrolimus, cyclo-
sporin, hydroxychloroquine do not show promising results [3, 19, 23].
2.1.3. Graham-Little syndrome (Piccardi-Lasseur syndrome)
It was first described by Piccardi in 1914 and the components of the disease were described by
Graham-Little in 1915. It has a triad of cicatricial alopecia of the scalp, noncicatricial alopecia of
axillae and pubic region and keratotic follicular papules over body and extremities [24].
Patients are generally females aged 30–70 years. The rate of incidence is four times higher in
women. Its exact etiology is not known, but it is thought to be a variant of lichen planopilaris
[24, 25]. Cellular immunity seems to play a role in the clinical manifestation. However, in a
number of cases, hepatitis B vaccination and genetic patterns were thought to be the causes
[26, 27]. In the early stages, alopecic patches-like lesions, perifollicular erythema occur in the
periphery of scalp [1, 22]. Atrophy is not observed even there is no loss in the hair follicles in
the axillae and pubic region. Follicular keratosis occurring mostly over body and extremities is
rarely observed on the eyebrows. Histopathological findings include follicular orthokeratotic
hyperkeratosis in the early lesions, perifollicular infiltrate of lymphocytes, and loss in
pilosebaceous unit. Similar to other cicatricial alopecias, fibrosis is observed in the advanced
stages [24, 25]. Treatment options may include topical and systemic corticosteroids, and cyclo-
sporine [24, 28].
2.2. Discoid lupus erythematosus
Cutaneous lupus erythematosus is a widespread disease group. It may be categorized into
three main entities: acute, subacute, and chronic. Discoid lupus erythematosus (DLE), is often
related to the cicatricial alopecia. Discoid lupus erythematosus most often affects women in 4th
and 5th decade of life. Its etiology is not fully understood [4, 29]. It seems that disease occurs
following the exposure to UV light of sensitive individuals accompanied by the increase in
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keratinocyte apoptosis and the induction of reactive T cell or immunocomplex-mediated
response [30, 31]. Compared to other lupus erythematosus forms, the course is benign and
transformation to systemic lupus erythematosus is less than 10%. Generalized forms of discoid
lupus tend to transform into systemic forms [1, 30, 31].
Approximately 20% of men with DLE and 50% of women exhibit cicatricial alopecia. Lesions are
clinically transformed from definite macules and papules into adhesive squams followed by
discoid plaques (coin-like shape). Plaques may be painful and itchy. In the course of time, these
lesions transform into atrophic plaques having peripheral hyperpigmentation, depigmentation
in the middle. Exposure to sun light and trauma may induce the disease [1, 30, 32]. Lesions
evolved to squamous cell carcinoma over years. Scalp hair involvement occurred during the first
year of disease. Patients generally consult a physician with complaints in hair loss increase and
itching. Rarely stinging, burning or scalp sensitivity may occur. Lesions are generally at the
vertex localization. Coupled with the centrifugal progression of lesions, plaques containing
follicular plugs are formed. Telangiectasia and atrophy are observed on plaques. Approximately
35% of DLE patients manifest a positive antinuclear antibody. Lupus band test is positive in 90%
of DLE lesions [4, 31, 32]. Histopathology of DLE reflects its clinical presentation. Epidermis is
generally atrophic. Vacuolar degeneration in basal keratinocytes and thickening in the basal
membrane are confirmed. Lymphocytic infiltrate is observed around veins and adnexal struc-
tures in the dermis. Mucin accumulation is the most significant indicator of cutaneous lupus
erythematosus. Collagen and elastic fibrils may get damaged. Lymphocytic infiltrate may diffuse
to the subcutaneous fatty tissue. In more than 90% of biopsies IgG and C3 depositions are
demonstrated immunopathologically. It is hard to presume the prognosis and course of DLE.
Newly diagnosed patients should be evaluated in terms of SLE. Complete physical examination,
routine blood tests, urine analysis and anti-dsDNA antibodies are examined. If it is negative, it is
regarded as skin-limited form [3, 29, 31, 33].
Differential diagnosis should consider lupus vulgaris, actinic keratosis, sarcoidosis, rosacea, psoriasis,
lichen planus granuloma annulare, tinea faciei, and seborrheic dermatitis. Clinically, histopathologi-
cal and immunological tests are favorable in differentiating from other diseases [1, 4].
First step of the therapy is to recommend sun protection. First-line therapy options include
corticosteroids and antimalarial agents. Corticosteroids are administered in forms of potent
topical corticosteroids or intralesional triamcinolone acetonide (4–10 mg/mL, monthly injec-
tions). Most frequently used antimalarial drug, hydroxychloroquine should be initially
started in doses of 200–400 mg daily. Pediatric posology is 4–6 mg/kg. Basal ophthalmolog-
ical examination and complete blood count should be performed. Side effects are rare and
include abdominal pain, anorexia, nausea, myalgia, skin hyperpigmentation, hematologic
changes, and ophthalmological damage. Oral corticosteroids can be used until efficacy has
been proven (1 mg/kg, tapering in 8 weeks). Oral retinoids can be tried in unresponsive
cases. For this purpose, acitretin (50 mg per day) or isotretinoin (40 mg per day) are used.
Moreover, topical immunomodulatory agents (e.g., tacrolimus), thalidomide, dapsone, and
oral vitamin C may be considered. If none of these treatments are found to be effective, oral
immunosuppressant therapies (mycophenolate mofetil, methotrexate, and azathioprine) are
initiated [31, 34–36].
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2.3. Classic pseudopelade of Brocq
It was first described by Brocq in 1888. It is frequently characterized as slowly progressing
disease with cicatricial alopecic patches without chronic inflammation [37–39]. The cause is not
known. There are many debates on accounting the disease. While some researchers believe
that Pseudopelade of Brocq is clinicopathologically different disease, some reported that it the
last phase of primary cicatricial alopecias. Consequently, successful determination of the dis-
ease is not available until this date. The epidemiology is not known. Although Pseudopelade
of Brocq may occur in both genders, it is more frequent in women over 40 years of age. It is
very rare in pediatric population. Although its etiopathogenesis is not fully understood, the
possible causes include genetics, autoimmunity, and infections [1, 38]. Pseudopelade of Brocq
is a chronic, and insidious form of primary cicatricial alopecia. There are usually no symptoms.
Mild itching may be present. Three clinical forms were identified by Brocq including scattered
small plaques, large plaques, and a combination of both. Vertex involvement is frequently
observed in all three forms. Patients rarely have squams. Small plaques showed confetti-like
scattering. Classic Pseudopelade of Brocq involves scalp, however, beard involvement occurs
too. The course of disease is slow and progressive but some cases rarely exhibit fast progres-
sion [3, 38]. Biopsy is significant to diagnose histopathologically. Two deep punch biopsies
along clinically active alopecic areas should be taken. To differentiate from other cicatricial
alopecias patients should undergo both routine and direct immunofluorescence examination.
Pseudopelade of Brocq does not have pathognomonic histopathological properties. In the
early lesions, there is mild perivascular and perifollicular lymphocyte infiltrate. However,
interphase changes are not present. Sebaceous glands are diminished or absent. Follicular
epithelial atrophy is present two deep punch biopsies along clinically active alopecic areas
should be taken two deep punch biopsies along clinically active alopecic areas should be taken
[40, 41]. As alopecia develops, atrophy becomes evident in the infundibular epithelium. Direct
immunofluorescence findings are usually negative. In the advanced stages, atrophic epidermis
is seen on the dermis containing follicular fibrotic bands extending to the subcutaneous tissue
[42, 43]. Differential diagnosis should include alopecia areata, lichen planopilaris, discoid
lupus erythematosus, and central centrifugal alopecia.
Treatment objective is to prevent clinical remission and progression of the disease. Unfortu-
nately, the progression still continues even after treatment [38, 44, 45]. Choice of therapy
depends mainly on activity, extent, and tolerance of the disease. In patients having less than
10% scalp involvement, topical or intralesional corticosteroid therapy is the first choice. There
are reports stating the efficacy of topical tacrolimus and topical minoxidil therapies. In addi-
tion, there are also reports indicating that systemic prednisolone, hydroxychloroquine, isotret-
inoin therapies are effective [36, 43, 44].
2.4. Central centrifugal cicatricial alopecia
It was first described by LoPresti et al. and also referred to as hot comb alopecia and follicular
degeneration syndrome [46]. It is the most common form of cicatricial alopecia in African
American females. Although its etiopathogenesis is not fully understood, the causes include
usage of hot comb, styling practices, chemical agents, infections, autoimmune diseases, and
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genetics [47, 48]. Clinically disease initiated at the vertex and middle of the scalp, as it pro-
gresses, it can cause centrifugal baldness. Symptoms such as itching or pain are often absent or
mild. Most of patients are adult black women [48, 49]. Histopathologic features include
perifollicular lymphocytic infiltrate, and fibrosis in the early stages. Terminal follicle count is
diminished. In the advanced stages, sebaceous gland and follicle loss are observed.
Dyskeratosis and epidermal mucin accumulation are absent. Perifollicular erythema and fol-
licular keratosis is usually absent. Pigment incontinence is minimal. Histopathology in the last
stage is similar to other cicatricial alopecias [48, 50]. Moreover, chronic transitional alopecia,
androgenic alopecia, alopecia areata, trichotillomania, folliculitis decalvans should be
excluded [1, 49, 51].
Treatment objective is to stop progression rather than hair growth. Regrowth is not possible
due to the formation of scar tissue. This is related to styling methods and even though this
relation is not confirmed, natural hair care techniques not causing trauma are recommended.
Hair care method involving chemicals and techniques causing traction should be eliminated
[3, 49–53]. Until the disease is stabilized, daily topical corticosteroids usage followed by three
times a week posology is recommended. 10 mg/ml doses of intralesional corticosteroids are
applied once a month for at least 6 months. The therapy is then continued depending upon the
symptoms. Especially in severe cases, oral anti-inflammatory drugs such as tetracycline are
applied for at least 6 months. In order to reduce itching and desquamation, seborrhoeic
dermatitis-like therapy (shampoos containing zinc pyrithione and/or ketoconazole) is
recommended. Antimalarial agents, minoxidil, thalidomide, cyclosporine, mycophenolate
mofetil, vitamins, and several herbal treatments are found to be effective. The treatment
should be continued at least 6 months and following enhancement, it should be lasted for a
year until the remission. Besides, hair transplantation may be performed. Wigs can also be
used [1, 36, 43, 49].
2.5. Alopecia mucinosa
It is also known as follicular mucinosis and characterized by the follicular papillary erythema
and squam formation in the perifollicular zone [4, 54]. All age groups can be affected and its
initiation can go to the infiltrate period. Its etiopathogenesis is not fully understood. Antigenic
stimulus T cell-related follicular response formed in hair follicles is thought to increase the
folliculotropic response.
Occurrence of lymphoproliferative diseases in 30% of adult patients is an important step in the
etiopathogenesis. Its course includes sharp-edged erythematous squamous plaques. The most
significant involvement occurs in the head and neck. Alopecia is seen when lesion affects hair
follicles. Dysesthesia and anesthesia can be observed in lesions [1, 55, 56]. Clinically, acne-
formed, hypopigmented, eczematous plaques and endured nodule forms are reported. Clini-
cally there are 3 types. Primary or benign type occurs in young patients and it is the only lesion
tending to improve in several years. Secondary or malignant type occurs in the elderly and it is
characterized by many lesions. Third type is chronic benign form having properties of both [4,
55, 57]. The most malignity associated with alopecia mucinosa is mycosis fungoides. Other
malignities include leukemia, Hodgkin lymphoma, renal carcinoma, lymphosarcoma. Its
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pathology reveals several mucin accumulation in follicular epithelium and sebaceous tissues,
perivascular, and perifollicular lymphocyte infiltrates. Dyskeratosis and lameller fibrosis are
absent [55, 57].
Differential diagnosis is performed by alopecia areata, telogen effluvium, lichen planopilaris,
morphea, tinea capitis, subcutaneous panniculitis-like T cell lymphoma, and dissecting follicu-
litis.
The most effective therapy in benign type alopecia mucinosa is intralesional steroid treatment.
There are a wide range of therapy options. These are topical oral antibiotics, topical retinoids,
steroids, dapsone, methotrexate, immunosuppressive agents, nitrogen mustard, and PUVA. In
the malignity-associated alopecia mucinosa direct malignity treatment should be performed.
Long term follow-ups are needed in chronic alopecia mucinosa [3, 36, 57, 58].
2.6. Keratosis follicularis spinulosa decalvans
Keratosis follicularis spinulosa decalvans (KFSD) is also known as keratosis pilaris decalvans. It
was first described by Siemens in 1926. It is characterized by scalp follicular hyperkeratosis and
photophobia. The end point is atrophy and cicatricial alopecia. Transition depending on X and
sporadic cases also occur. It is thought to be a part of keratosis pilaris atrophicans [59–61]. Its
etiology is not known. It is usually initiated around facial with follicular hyperkeratosis in the
early life. Later on, it spreads on scalp, hair, and eyelashes. Patch-like alopecia on scalp, hair, and
eyelashes occurs and it is followed by cicatrices is observed on alopecic areas. Reddish-brown
telangiectasia on lesions can be seen. Moderate itching is present. Staphylocuccus aureus-related
pustule infections can worsen the disease. The disease is generally more severe in men [4, 62, 63].
Histopathologic examination revealed intrafollicular and perifollicular edema and neutrophil
infiltrate. As the disease progresses, mucin accumulation around the top of follicles and
perivascular and perifollicular lymphocyte infiltration are detected [3, 61, 62].
Differential diagnosis should include KID syndrome, lichen planopilaris, and folliculitis
decalvans.
Treatment should be done especially in childhood where the disease is active. Unfortunately,
there is no specific treatment. Topical and intralesional corticosteroids, oral retinoids, and
dapsone can be used [63, 64].
3. Neutrophilic cicatricial alopecias
3.1. Folicullitis decalvans
Folicullitis decalvans is a disease occurred in pustules on scalp. The cause is not known.
Some researchers blame isolation of S. aureus in the pustular lesions as its etiology. Immune
interaction between microorganisms and the host is thought to be the most significant factor
in folliculitis development. Its epidemiology is not fully known. It is one of most important
causes of cicatricial alopecia. The prevalence is same in both genders [65–67]. Clinically
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initial lesion is erythema follicular pustule and papule. These can be painful and itchy. Later,
new pustules are observed and accumulated to form pustular milier abscess (Figure 2).
Consequently, cicatricial alopecia plaques have been formed [67]. Tufted folliculitis is char-
acterized by having more than one hair on dilated orificial follicles. It is often seen in
folliculitis decalvans [67, 68]. Concurrently DLE, LPP, acne keloid, and tinea capitis can occur
during the course. In order to diagnose folliculitis decalvans, biopsy must be taken from
pustules. Although pathognomonic findings are absent in the histopathological evaluation,
follicular neutrophilic pustules in the early stages, plasma cells in chronic period are seen. As
a response to follicular damage, foreign matter granules can be formed and consequently
common fibrosis occurs. Careful histological and clinical evaluation should be carried out
even after the diagnosis since the disease can overlap with other alopecias. Diagnosis should
take into consideration of dissecting folliculitis, acne keloid, erosive pustular dermatosis,
acne necrotica, DLE, CCCPA, LPP, and pseudopelade [67, 68].
Bacterial cultures should be taken from each patient and antibiotic resistance should be
determined prior treatment. Long-term antibiotics targeting S. Auerus must be used. Tetracy-
cline, coloxylin, erythromycin is used as first-line therapy. Antibiotic treatment is initiated as
in acne and reduced according to the response. The disadvantage of antibiotic therapy is
recurrence. Clindamycin and rifampicin is used in combination in unresponsive patients.
Other effective choice of therapy is isotretinoin. It can be administered intralesionally in fast
progressive cases. Other treatments include dapsone, hydroxychloroquine, adalimumab,
infliximab. Wigs can be recommended as cosmetic camouflage in patients with cicatricial
alopecia [36, 69, 70].
3.2. Dissecting cellulitis
Described by Hoffman in 1908, it is also known as perifolliculitis capitis abscedens et
suffodiens. It forms follicular occlusion triad along with acne conglobate and hidradenitis
Figure 2. Folliculitis decalvans; pustules on the scalp are noticed.
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suppurativa. If pilonidal cysts are added to the picture, they all referred as tetrad. Dissecting
cellulitis most commonly affects young black men with an average age of 18–40 years.
Although its etiopathogenesis remains shrouded in mystery, S. aureus-induced neutrophilic
response is the cause. It seems genetically transferred disease since familial cases have been
reported [71, 72]. Initial lesion is generally follicular pustules at the vertex. Later, these are
transformed into painful nodules. Accumulated nodules form tubular bridges. Seropurulent
discharge can occur on nodules. Skin can be covered by crut and squams. Hypertrophic and
keloid scar atrophy and cicatricial alopecia may occur in patients treated insufficiently.
Although spontaneous remission occurs, relapse is frequent. Cervical and occipital lymphade-
nopathy may be observed [1, 3, 72].
In its histopathology, perifolliculitis formed by lymphocyte around follicles, histiocyte and
polymorphous nuclear cells is present. Superficial fat tissue and abscess formation may be
observed in dermis. Intensive fibrosis occurs in the late stages [71, 72].
Medical treatment of dissecting folliculitis involves high doses of isotretinoin. Antibiotics such
as minocycline, tetracycline, erythromycin, clindamycin along with zinc sulfate, dapsone,
colchicine, corticosteroids can be recommended as other treatment options. In persistent cases,
surgical interventions such as excision and grafting may be considered [73–76].
4. Mixed cicatricial alopecias
4.1. Acne keloidalis
Acne keloidalis was first described in 1869 by Kohn. This disease is also known as folliculitis
keloidalis nuchae or folliculitis keloidalis. The term acne keloidalis is somewhat of a misnomer
since the condition is neither a kind of acne nor keloidal in nature. Acne keloidalis is most often
seen in African Americans. The prevalence in American football players is 15%. Mechanical
trauma, infections, autoimmunity, and drugs are the causes in its etiopathogenesis [76–78]. It is
clinically developed in the early stages on the occipital scalp and on the nape of the neck as
reddish-brown colored papules with smooth surface. Occasionally, these papules transformed
into nodules and plaques. Pustules and abscesses are rarely occurred. Intrafollicular and
perifollicular lymphocytes and plasma cell infiltrates are histopathologically involved in the
early lesions. In the advanced stages, follicular destruction develops. Sebaceous glands disap-
pear. Differential diagnosis should include folliculitis decalvans, acne necrotica, and dissecting
folliculitis [1, 76].
First-line therapy of acne keloidalis is prevention. Preventing trauma and infections is impor-
tant. In mild cases, combination of potent topical corticosteroids with topical antibiotics is
advantageous. Oral tetracycline may be added to the monthly injections of intralesional corti-
costeroids. Partial response can be obtained by cryotherapy and laser therapy. Effective lasers
include carbon dioxide, 1064 nm Nd:YAG or 810 nm diode. Surgical excision may be needed
for common keloidal plaques. Surgical approaches include excision with primary closure or
secondary intention healing. Deep surgical excision is more efficient. Surgical excision is an
effective option [36, 79, 80].
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4.2. Acne necrotica
Acne necrotica is also known as folliculitis necrotica. It is a mysterious disease not under-
stood by many dermatologists. Infections are routinely mentioned in its etiology but evidence
cannot be demonstrated. Drugs and food allergies are also thought to be the cause. Mechan-
ical factors such as itching only spread the disease. Most of patients are women. Lesions are
generally observed on the scalp along face and hairline. They are rarely occurred on nose and
cheeks [4, 81, 82]. Initial lesions are umbilicated follicular papules. Not long after, they
transformed into pustules. Consequently, varioliform scars may develop. Initially
perivascular and perifollicular lymphocytic infiltrate, subepidermal edema is apparent. In
the advanced stages, necrosis is observed in the follicular epithelium and epidermis [3, 81].
Neutrophiles can be seen in superficial dermis. Differential diagnosis should also include
folliculitis decalvans, dissecting folliculitis, colitis, eczema herpeticum, and molluscum
contagiosum [81, 82].
Treatment with oral tetracycline, antistaphylococcal antibiotics may be effective. They should
be used in long term. In patients not having complete response, topical or intralesional corti-
costeroid can be added. Isotretinoin treatment may prolong the remission period [4, 43].
4.3. Erosive pustular dermatosis
The disease was first described in 1979 by Pye et al. and about 100 cases have been reported so
far [83]. The disease most commonly occurs in elderly and females. Sun damage, local trauma
(surgery, cryotherapy, herpes zoster), and autoimmunity are blamed in its etiology. Lesions
with crusts and pustules on atrophic skin are clinically observed. The number of pustules can
vary remarkably, and in some cases they are absent. Pain and pruritus in the lesions are not
observed. However, cicatricial alopecia may develop in the advanced stages. Histopathology is
uncharacteristic and not very helpful in confirming the diagnosis [84, 85]. Histopathological
examination is crucial to exclude other diseases. Histopathology shows subcorneal pustules,
epidermal atrophy, and erosions. In addition, these findings can be accompanied by a poly-
morphous dermal inflammatory infiltrate and in some cases leukocytoclastic vasculitis might
be present. The differential diagnosis should consider tinea capitis, Gram-negative folliculitis,
pyoderma gangrenosum, DLE, pemphigus vulgaris, and SCC. High-potency topical steroids
reduce the inflammation significantly [1, 85].
Steroids must be used more than 6 months for better responses. Other treatment options
include tacrolimus, dapsone, calcipotriol, and acitretin. Sun protection is reported to be effec-
tive since disease etiology includes actinic damage [86, 87].
5. Conclusion
Cicatricial alopecia forms an important group of disorders that end up with scarring and
persistent hair loss. An elaborate physical examination, skin biopsies and blood tests can be
helpful in order to establish the accurate diagnosis and to suggest the most appropriate
treatment for the hair loss. Many patients do not respond to the first treatment they receive
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and the condition frequently relapses when treatment is stopped. Some clinics offer surgical
treatment, such as scalp reduction surgery and hair transplantation, but it may not be suitable
for all patients. Patients often have significant psychosocial impact and management of these
patients should address not only their physical but also psychological aspects.
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